Analysts picks & changes

Analysts picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/3 cls
AtheroGenics (AGIX) Lazard Joel Sendek Price target Buy 1% $24.89
Sendek lowered his price target to $48 from $60 after final Phase IIb data showed that AGIX's AGI-1067 did not give a significant reduction in plaque volume compared to placebo in treating atherosclerosis. The compound did show a significant reduction from baseline.

Read the full 655 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE